会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Promotion of wound healing by chemically-modified tetracyclines
    • 通过化学改性的四环素促进伤口愈合
    • US5827840A
    • 1998-10-27
    • US691135
    • 1996-08-01
    • Nungavaram S. RamamurthyLorne M. GolubThomas F. McNamara
    • Nungavaram S. RamamurthyLorne M. GolubThomas F. McNamara
    • A61K31/65A61K45/06A61L15/44A61P17/02
    • A61L15/44A61K31/65A61K45/06A61L2300/406A61L2300/41A61L2300/412
    • A method for improving the healing response of epithelialized tissue (e.g., skin, mucosae) to acute traumatic injury is disclosed. The method includes employing a tetracycline compound, having substantially no antibacterial activity, to improve the capacity of the epithelialized tissue to heal acute wounds. Specifically, the method involves increasing the rate of collagen accumulation of the healing epithelialized tissue above that associated with wound healing in the individual. The method decreases proteolytic activity in the epithelialized tissue by means of the tetracycline compound, most commonly decreasing collagenolytic activity and/or decreasing gelatinolytic activity. Collagenase and gelatinase activity have been shown to be decreased by the method of the invention. Preferably, the method is employed to improve the wound healing capacity of human or animal subjects in whom such capacity is impaired. Also, the non-antibiotic tetracycline is preferably administered topically at the site of the wound.
    • 公开了一种改善上皮组织(例如皮肤,粘膜)对急性创伤性损伤的愈合反应的方法。 该方法包括使用基本上没有抗菌活性的四环素化合物,以改善上皮组织治愈急性创伤的能力。 具体地说,该方法包括增加愈合上皮组织的胶原蛋白积累速率高于个体伤口愈合以上。 该方法通过四环素化合物降低上皮组织中的蛋白水解活性,最常降低胶原分解活性和/或降低明胶溶解活性。 通过本发明的方法已显示胶原酶和明胶酶活性降低。 优选地,该方法用于改善受损的人或动物受试者的伤口愈合能力。 此外,非抗生素四环素优选在伤口部位局部施用。
    • 7. 发明授权
    • Therapeutic method for management of diabetes mellitus
    • 治疗糖尿病的治疗方法
    • US5929055A
    • 1999-07-27
    • US880945
    • 1997-06-23
    • Maria Emanuel RyanLorne M. GolubNungavaram S. RamamurthyThomas F. McNamara
    • Maria Emanuel RyanLorne M. GolubNungavaram S. RamamurthyThomas F. McNamara
    • A61K45/00A61K31/155A61K31/175A61K31/426A61K31/65A61K38/28A61P3/10
    • A61K38/28Y10S514/866
    • A method for treating diabetes in a mammal by moderately controlling blood glucose concentration in the mammal together with administering to the mammal an amount of a tetracycline compound effective to reduce complications associated with diabetic hyperglycemia. The method enables long term management of diabetes by avoiding the problems associated with tight control of blood glucose concentrations, i.e., hypoglycemia tolerance and seizures, while simultaneously avoiding the problems associated with conventional moderate control of blood glucose concentrations, i.e., pathological complications associated with hyperglycemia, such as nephropathy, retinopathy, etc. Blood glucose concentration can be controlled by moderate administration (e.g., fewer injections per day) of insulin or another glucose-modulating agent, while pathological complications characteristic of diabetic hyperglycemia are ameliorated through the activity of tetracycline compound, the latter preferably administered in an amount that is substantially non-antimicrobial.
    • 一种通过适度控制哺乳动物中的血糖浓度来治疗哺乳动物的糖尿病的方法,同时向哺乳动物施用一定量的有效减少与糖尿病性高血糖相关并发症的四环素化合物。 该方法能够通过避免与血糖浓度的严格控制(即低血糖耐受和癫痫发作)相关的问题,同时避免与常规的中度控制血糖浓度相关的问题,即与高血糖相关的病理性并发症 ,如肾病,视网膜病变等。血糖浓度可以通过中度给药(例如,每天更少的注射)胰岛素或另一种葡萄糖调节剂来控制,而通过四环素化合物的活性来改善糖尿病性高血糖症状的病理并发症 ,后者优选以基本上非抗微生物的量施用。